Latest news and press releases about Emergent BioSolutions Inc. (EBS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations.
Price
| Price | $6.75 |
| Market Cap | $348M |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | 0.99 |
| EV / EBITDA | -31.72 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -35.91% |
| Return on Invested Capital | -5.47% |
| Return on Assets | -15.83% |
| Gross Margin | 49.40% |
| Operating Margin | -7.06% |
| Net Margin | -22.96% |
Related companies: AQST · CMPS · CRVS · ESPR · OLMA · ORGO · PRTA
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of EBS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks